Elacestrant with or without abemaciclib for endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new hormone therapy (elacestrant) alone or combined with a targeted pill (abemaciclib) for people with advanced or recurrent endometrial cancer that is hormone-receptor-positive. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or recurrent endometrial cancer that has not been cured by other treatments.
- Your cancer cells tested positive for estrogen receptors (ER-positive).
- You have previously received platinum-based chemotherapy, and no more than 2 prior treatments for your cancer.
- You have not taken elacestrant or other similar oral SERD drugs before, nor any CDK4/6 inhibitor (like abemaciclib or palbociclib).
- You are willing to use effective birth control during the study if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
This trial tests a combination of two medications (elacestrant and everolimus) to treat advanced or recurrent endometrial cancer that has hormone receptors. The drugs work by blocking cancer cell growth pathways, and this study explores whether using them together is safe and effective for patients whose cancer has progressed despite previous treatment.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.